CN101342338B - Medicament for treating hepatopathy - Google Patents

Abstract

The present invention discloses a medicine which is used for treating liver disease. The medicine is prepared from Chinese medicinal materials according to the following weight portions: 50 to 80 portions of leech, 150 to 200 portions of herba artemisiae, 80 to 100 portions of notoginseng, 20 to 40 portions of carapax amydae, 50 to 80 portions of tortoise plastron, 100 to 130 portions of powder of buffalo horn, 120 to 180 portions of fructus schizandrae, 80 to 120 portions of burreed, 80 to 120 portions of zedoary turmeric, 160 to 180 portions of alga, 160 to 180 portions of laminaria japonica, 250 to 350 portions of coix lacryma-jabi, 50 to 80 portions of Astraolylis lancea formalyrata, 130 to 160 portions of pseudostellaria root, 50 to 80 portions of Tuyuan, 150 to 250 portions of oldenlandia diffusa, and 50 to 80 portions of licorice. The clinical test has proven that the medicine has the characteristics of mature technology, security, reliability, less adverse reactions, tolerance of patients, low costs, and so on. Moreover, the medicine can be easily promoted and applied, and has broad prospects of application.

Description

A kind of medicine for the treatment of hepatopathy

Technical field

The present invention relates to a kind of Chinese Traditional Medicines for the treatment of chronic hepatitis, liver cirrhosis.

Background technology

Chronic hepatitis, liver cirrhosis are the interior paraplasm pathology processes of fibrous connective tissue of hepatocyte inflammation, necrosis, liver that various different virulence factors cause, being the common pathological basis of various chronic hepatopathys, also is that the touching difficulty of hepatic lesions is more to the main cause that develops into malignant change.In China's viral hepatitis is the main cause that causes liver cirrhosis; data shows according to statistics, and China HbSAg carrier is 9.75% at present, about 1.2 hundred million people; about 3,000 ten thousand people of chronic viral hepatitis B patient only; wherein have 20% can develop into liver cirrhosis approximately, about 3% can develop into hepatocarcinoma, and in a single day patient enters the liver cirrhosis course of disease; quality of life will obviously descend; crisis life gradually has a strong impact on the people's health, and is very harmful.

How effectively treating chronic hepatitis, solve the paraplasm of hepatic fibrosis connective tissue and the liver cirrhosis that causes, improve and improve patient's quality of life, is one of difficult problem of our times medical domain.At this obstinate disease, how to use Chinese medicine increasingly important better to the hepatitis due to a variety of causes, research and development that liver cirrhosis is effectively treated project, especially can provide a kind of safe and reliable, untoward reaction is few, the patient all can tolerate, the Chinese patent medicine of treatment the hepatopathy cheap and easy to utilize most important thing especially.

Summary of the invention

Task of the present invention is to provide a kind of medicine for the treatment of hepatopathys such as chronic hepatitis, liver cirrhosis.

Its technical solution is:

A kind of medicine for the treatment of hepatopathy, the medicament of making by following raw material of Chinese medicine: (consumption is a weight portion)

Hirudo 50～80, Herba Artemisiae Scopariae 150～250, Radix Notoginseng 80～100, Carapax Trionycis 20～40, Carapax et Plastrum Testudinis 50～80, Cornu Bubali powder 100～130, Fructus Schisandrae Chinensis 120～180, rhizoma sparganic 80～120, Rhizoma Curcumae 80～120, Sargassum 160～180, Thallus Laminariae (Thallus Eckloniae) 160～180, Semen Coicis 250～350, the Rhizoma Atractylodis Macrocephalae 50～80, Radix Pseudostellariae 130～160, eupolyphaga 50～80, Herba Hedyotidis Diffusae 150～250 and Radix Glycyrrhizae 50～80.

Medicine of the present invention, preferred weight (part) proportioning is:

Hirudo 60, Herba Artemisiae Scopariae 200, Radix Notoginseng 90, Carapax Trionycis 30, Carapax et Plastrum Testudinis 60, Cornu Bubali powder 120, Fructus Schisandrae Chinensis 150, rhizoma sparganic 100, Rhizoma Curcumae 100, Sargassum 150, Thallus Laminariae (Thallus Eckloniae) 150, Semen Coicis 300, the Rhizoma Atractylodis Macrocephalae 60, Radix Pseudostellariae 150, eupolyphaga 60, Herba Hedyotidis Diffusae 200 and Radix Glycyrrhizae 60.

Medicine of the present invention, its medicament are pill, granule or powder.

Chinese medical discrimination is thought and is surely belonged to " deficiency in origin and excess in superficiality " by liver cirrhosis it " amasss " opinion and controls category, with its positive QI-insufficiency, disorder of QI and blood (deficiency in origin), cause congestion resistance network, form long-pending (mark is real) for main pathogenesis and in whole pathological process, have cards such as the deficiency of YIN, damp and hot, expectorant silt, the stagnation of QI, the deficiency of vital energy simultaneously concurrently with fixed attention, liver histopathology is observed shown that the fibrous connective tissue hypertrophy is one of main pathological characters of clinical blood stasis disease patient in the liver clinically.At " weakened body resistance " and " blood stasis " these two key factors, medicine of the present invention is a principle with strengthening vital QI to eliminate pathogenic factors, treating both the principal and secondary aspects of a disease, and in prescription medicine, not only meet tcm theory, and again in conjunction with modern Chinese medicine pharmacological research achievement, that is: the application that in the developing of hepatitis, liver cirrhosis, plays an important role in the variation of treatment hepatic parenchymal cells damage and human body immune function of Chinese medicine etc.It makes the raw material of Chinese medicine that medicament adopts Hirudo, Herba Artemisiae Scopariae, Radix Notoginseng, Carapax Trionycis, Carapax et Plastrum Testudinis, Cornu Bubali powder, Fructus Schisandrae Chinensis, rhizoma sparganic, Rhizoma Curcumae, Sargassum, Thallus Laminariae (Thallus Eckloniae), Semen Coicis, the Rhizoma Atractylodis Macrocephalae, Radix Pseudostellariae, eupolyphaga, Herba Hedyotidis Diffusae and Radix Glycyrrhizae.Wherein Radix Pseudostellariae, Fructus Schisandrae Chinensis, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae, replenishing QI to invigorate the spleen nourishing YIN and dispelling dampness, Carapax Trionycis, Carapax et Plastrum Testudinis, Sargassum, Thallus Laminariae (Thallus Eckloniae), nourishing YIN and clearing away heat hard masses softening and resolving, more than two groups of strengthening vital QI to eliminate pathogenic factors, in order to effect a permanent cure.Cornu Bubali powder, Herba Artemisiae Scopariae, Herba Hedyotidis Diffusae, Semen Coicis, clearing away heat-damp and promoting diuresis detoxifcation, Hirudo, Radix Notoginseng, eupolyphaga, rhizoma sparganic, Rhizoma Curcumae, removing blood stasis blood-activating and qi-promoting, change silt eliminating stagnation, after this two groups is main in order to take stopgap measures with eliminating evil, and all medicines share, benefiting qi and nourishing yin, heat-clearing and toxic substances removing, activating blood circulation to dissipate blood stasis, hard masses softening and resolving.Clinical practice has good anti-liver cirrhosis, improves human body immune function and slows down the effect that hepatic parenchymal cells damages.Chronic hepatitis, liver cirrhosis are had the comprehensive adjustment function, and have to set upright and do not hold back heresy, eliminating evilly do not hinder positive characteristics.Be used for the treatment of chronic hepatitis, liver cirrhosis; can improve clinical symptoms; can make HBeAg and HBV-DNA turn out cloudy, reduce the ratio (A/G) of glutamate pyruvate transaminase (ALT), serum bilirubin (SB), albumin and globulin again significantly, improve and liver function protecting, and without any side effects.

In addition, by clinical verification, that medicine of the present invention possesses skills is ripe, safe and reliable, untoward reaction is few, the patient all can tolerate and lower-price characteristic, and is easy to utilize, has broad application prospects.

The specific embodiment

Embodiment 1

Take by weighing raw material (gram) by following proportioning:

Hirudo 50, Herba Artemisiae Scopariae 150, Radix Notoginseng 80, Carapax Trionycis 20, Carapax et Plastrum Testudinis 50, Cornu Bubali powder 100, Fructus Schisandrae Chinensis 120, rhizoma sparganic 80, Rhizoma Curcumae 80, Sargassum 160, Thallus Laminariae (Thallus Eckloniae) 160, Semen Coicis 250, the Rhizoma Atractylodis Macrocephalae 50, Radix Pseudostellariae 130, eupolyphaga 50, Herba Hedyotidis Diffusae 150 and Radix Glycyrrhizae 50.

Preparation method is as follows:

Herba Artemisiae Scopariae in the above-mentioned raw material of Chinese medicine, Herba Hedyotidis Diffusae, the Rhizoma Atractylodis Macrocephalae, rhizoma sparganic, Hirudo, Carapax Trionycis, Fructus Schisandrae Chinensis, Rhizoma Curcumae, Sargassum, Thallus Laminariae (Thallus Eckloniae), Semen Coicis, Radix Pseudostellariae, eupolyphaga, Radix Glycyrrhizae are added 8 times of water gagings to be soaked 1 hour, decoct 1.5h, filter, gained once decocts filtrate device storage in addition, and medicinal residues decoct with water 1.5h again; Filter, the gained secondary decocts filtrate and once decocts filtrate mixing with aforementioned, is concentrated into proportion 1.20 under 80 ℃ of conditions, makes thick paste (standby).It is standby that residue raw material of Chinese medicine pulverizing mixing is made fine powder.

After fine powder and thick paste made soft material with blender, the reuse pellet processing machine was made concentrated pill, polishing then, dried, selects ball, packing, censorship.

Embodiment 2

Take by weighing raw material (gram) by following proportioning:

Hirudo 80, Herba Artemisiae Scopariae 250, Radix Notoginseng 100, Carapax Trionycis 40, Carapax et Plastrum Testudinis 80, Cornu Bubali powder 130, Fructus Schisandrae Chinensis 180, rhizoma sparganic 120, Rhizoma Curcumae 120, Sargassum 180, Thallus Laminariae (Thallus Eckloniae) 180, Semen Coicis 350, the Rhizoma Atractylodis Macrocephalae 80, Radix Pseudostellariae 160, eupolyphaga 80, Herba Hedyotidis Diffusae 250 and Radix Glycyrrhizae 80.

Preparation method is as follows:

Herba Artemisiae Scopariae in the above-mentioned raw material of Chinese medicine, Herba Hedyotidis Diffusae, the Rhizoma Atractylodis Macrocephalae, rhizoma sparganic, Hirudo, Carapax Trionycis, Fructus Schisandrae Chinensis, Rhizoma Curcumae, Sargassum, Thallus Laminariae (Thallus Eckloniae), Semen Coicis, Radix Pseudostellariae, eupolyphaga, Radix Glycyrrhizae are added 8 times of water gagings to be soaked 1 hour, decoct 1.5h, filter, gained once decocts filtrate device storage in addition, and medicinal residues decoct with water 1.5h again; Filter, the gained secondary decocts filtrate and once decocts filtrate mixing with aforementioned, is concentrated into proportion 1.20 under 80 ℃ of conditions, makes thick paste (standby).It is standby that residue raw material of Chinese medicine pulverizing mixing is made fine powder.

After fine powder and thick paste made soft material with blender, the reuse pellet processing machine was made concentrated pill, polishing then, dried, selects ball, packing, censorship.

Embodiment 3

Take by weighing raw material (gram) by following proportioning:

Hirudo 60, Herba Artemisiae Scopariae 200, Radix Notoginseng 90, Carapax Trionycis 30, Carapax et Plastrum Testudinis 60, Cornu Bubali powder 120, Fructus Schisandrae Chinensis 150, rhizoma sparganic 100, Rhizoma Curcumae 100, Sargassum 150, Thallus Laminariae (Thallus Eckloniae) 150, Semen Coicis 300, the Rhizoma Atractylodis Macrocephalae 60, Radix Pseudostellariae 150, eupolyphaga 60, Herba Hedyotidis Diffusae 200 and Radix Glycyrrhizae 60.

Preparation method is as follows:

Herba Artemisiae Scopariae in the above-mentioned raw material of Chinese medicine, Herba Hedyotidis Diffusae, the Rhizoma Atractylodis Macrocephalae, rhizoma sparganic, Hirudo, Carapax Trionycis, Fructus Schisandrae Chinensis, Rhizoma Curcumae, Sargassum, Thallus Laminariae (Thallus Eckloniae), Semen Coicis, Radix Pseudostellariae, eupolyphaga, Radix Glycyrrhizae are added 8 times of water gagings to be soaked 1 hour, decoct 1.5h, filter, gained once decocts filtrate device storage in addition, and medicinal residues decoct with water 1.5h again; Filter, the gained secondary decocts filtrate and once decocts filtrate mixing with aforementioned, is concentrated into proportion 1.20 under 80 ℃ of conditions, makes thick paste (standby).It is standby that residue raw material of Chinese medicine pulverizing mixing is made fine powder.

After fine powder and thick paste made soft material with blender, the reuse pellet processing machine was made concentrated pill, polishing then, dried, selects ball, packing, censorship.

Medicine of the present invention, its medicament also can be made into powders such as granule or powder; Also can be made into other suitable dosage forms.

Other relevant issues are described as follows:

1, indication:

Being adapted to chronic hepatitis has early stage liver cirrhosis sign or compensatory phase of liver cirrhosis, and it is low etc. to be streak, tuberosity (eliminating hepatocarcinoma), splenomegaly, the broadening of the door splenic vein, globulin height, albumin as echo in the liver.

2, instructions of taking:

Each 9g, 2 times/day or follow the doctor's advice and take.

3, points for attention:

If take and occur skin, mucosal bleeding in the process, give decrement or withdraw.

4, treatment chronic hepatitis, liver cirrhosis 100 examples and clinical observation:

From in January, 2005-2007 year December, use Drug therapy chronic hepatitis of the present invention, liver cirrhosis 100 examples, and share compound liver-benepitino remedy treatment contrast with 100 routine AOTAILE, obtain satisfactory effect.

Clinical data

100 examples are organized in treatment and matched group 100 examples all derive from January, the 2005-2007 year December chronic viral hepatitis B outpatient service of the court's liver and gall internal medicine and the case history of being in hospital.By the viral hepatitis diagnostic criteria of the 5th the national infectious disease parasitic disease academic conference revision in Beijing in May nineteen ninety-five, all the case course of disease is all more than half a year.Treatment is organized in 100 examples, 56 examples that chronic hepatitis is slight, moderate 43 examples, severe 1 example; Male's 62 examples, women's 38 examples, M-F is 1.6:1; Age is 17-73 year, 34 years old mean age; The course of disease is 2-21, average out to 4.3 years.In matched group 100 examples, 61 examples that chronic hepatitis is slight, moderate 36 examples, severe 3 examples; Male's 69 examples, women's 31 examples, men and women's ratio is 2.2:1; Age is 15-68 year, 32 years old mean age; The course of disease is November-24 year, average out to 3.7 years.Two groups of cases are learned by statistics at aspects such as the state of an illness, sex, age, the courses of disease and are handled difference and do not have significance (P〉0,05).

Therapeutic Method

The treatment group: take medicine of the present invention every day twice, each 9 grams, 3 months is a course of treatment.Through controlling 1-3 the course of treatment, finish check 5 indexs of serum HBV and HBV-DNA per course of treatment, liver function deviant's check in every month liver function 1 time.

Matched group: 1 time 9 gram of AOTAILE, three times on the one; Compound liver-benepitino remedy, 3 times on the one, one time 3.3 months is 1 course of treatment.Treatment time and detection method are with the treatment group.

Comparison of therapeutic

1, two groups of clinical efficacies are relatively: 100 examples are organized in treatment, clinical basic healing 48 (48%), and produce effects 39 examples (39%), 9 examples that take a turn for the better (9%), invalid 4 examples (4%), total effective rate is 95%.Matched group 100 examples, clinical basic healing 31 examples (31%), produce effects 14 examples (14%), 28 examples that take a turn for the better (28%), invalid 27 examples (27%), total effective rate 72%.Two groups of total effective rates have significance (P＜0,05 or P 0,01), the treatment group obviously is better than matched group.

2, two groups of HBeAg and HBV-DNA turn out cloudy effect relatively: HBeAg positive person 87 examples before the treatment of treatment group, and 79 examples of turning out cloudy after the treatment, negative conversion rate is 90,8%; Positive person's 38 examples before the HBV-DNA treatment, 29 examples of turning out cloudy after the treatment, negative conversion rate 76%.HBeAg positive person 85 examples before the treatment of control group, 41 examples of turning out cloudy after the treatment, negative conversion rate is 48.2%; Positive person's 36 examples before the HBV-DNA treatment, 11 examples of turning out cloudy after the treatment, negative conversion rate 30.6%.Two groups are relatively, no matter HBeAg negative conversion rate, or HBV-DNA negative conversion rate, and the treatment group is all apparently higher than matched group, and both differences have highly significant meaning (P＜0,01).

3, treatment group and matched group liver function recovery effect compare: unusual person's 89 examples of glutamate pyruvate transaminase (ALT) before the treatment of treatment group, recover normal person's 84 examples, effective percentage 94,3%, (84/89) after the treatment; Unusual person's 73 examples of serum bilirubin (SB), normal person's 67 examples, effective percentage 91.8% (67/73) are recovered in the treatment back; Albumin and unusual person's 61 examples of the ratio (A/G) of globulin, normal person's 54 examples, effective percentage 88.5% (54/61) are recovered in the treatment back.3 index effective percentage of matched group liver function are respectively ALT94.3%, SB91.8%, A/G88.5%.Difference has highly significant between two groups, and the treatment group is apparently higher than matched group (P＜0,01).

Toxicity

Any bad toxicity does not all take place in two groups of cases in therapeutic process.

Claims (2)

1. medicine for the treatment of hepatopathy is characterised in that it is the medicament of being made by the following weight Chinese medicinal raw materials:

Hirudo 50～80, Herba Artemisiae Scopariae 150～250, Radix Notoginseng 80～100, Carapax Trionycis 20～40, Carapax et Plastrum Testudinis 50～80, Cornu Bubali powder 100～130, Fructus Schisandrae Chinensis 120～180, rhizoma sparganic 80～120, Rhizoma Curcumae 80～120, Sargassum 160～180, Thallus Laminariae (Thallus Eckloniae) 160～180, Semen Coicis 250～350, the Rhizoma Atractylodis Macrocephalae 50～80, Radix Pseudostellariae 130～160, eupolyphaga 50～80, Herba Hedyotidis Diffusae 150～250 and Radix Glycyrrhizae 50～80.

2. medicine for the treatment of hepatopathy is characterised in that it is the medicament of being made by the following weight Chinese medicinal raw materials:

Hirudo 60, Herba Artemisiae Scopariae 200, Radix Notoginseng 90, Carapax Trionycis 30, Carapax et Plastrum Testudinis 60, Cornu Bubali powder 120, Fructus Schisandrae Chinensis 150, rhizoma sparganic 100, Rhizoma Curcumae 100, Sargassum 150, Thallus Laminariae (Thallus Eckloniae) 150, Semen Coicis 300, the Rhizoma Atractylodis Macrocephalae 60, Radix Pseudostellariae 150, eupolyphaga 60, Herba Hedyotidis Diffusae 200 and Radix Glycyrrhizae 60.